Bevacizumab does not inhibit the formation of liver vessels and liver regeneration following major hepatectomy: a large animal model study
O Troup, A Skalicky, L Vistejnova, P Klein, A Maleckova… - in vivo, 2022 - iv.iiarjournals.org
Background/Aim: Patients with unresectable liver colorectal cancer metastases are treated
with neoadjuvant chemotherapy often accompanied by biological therapy aimed at reducing …
with neoadjuvant chemotherapy often accompanied by biological therapy aimed at reducing …
Bevacizumab impairs hepatocyte proliferation after partial hepatectomy in a rabbit model
A Dupre, A Paradisi, S Langonnet, A Gandini… - Anticancer …, 2012 - ar.iiarjournals.org
Background: Bevacizumab is used to treat patients with metastatic colorectal cancer,
including those who will undergo liver surgery. The effects of this agent on the regenerative …
including those who will undergo liver surgery. The effects of this agent on the regenerative …
The impact of bevacizumab on liver regeneration following hepatectomy in rats.
H Mori, M Shimada, T Utsunomiya, S Imura… - Journal of Clinical …, 2011 - ascopubs.org
228 Background: In our clinical data, we had the interesting findings that the pathologic
sinusoidal obstruction syndrome and serum hyaluronic acid after neoadjuvant oxaliplatin …
sinusoidal obstruction syndrome and serum hyaluronic acid after neoadjuvant oxaliplatin …
Preoperative bevacizumab and volumetric recovery after resection of colorectal liver metastases
Background and Objectives While preoperative treatment is frequently administered to
CRLM patients, the impact of chemotherapy, with or without bevacizumab, on liver …
CRLM patients, the impact of chemotherapy, with or without bevacizumab, on liver …
[HTML][HTML] Administration of anti-vascular endothelial growth factor antibody following hepatectomy does not inhibit remnant liver regeneration or growth of remnant …
K Kasuya, M Suzuki, Y Nagakawa… - Experimental and …, 2012 - spandidos-publications.com
In addition to the use of chemotherapeutic agents for the prevention of multiple liver
metastases from colorectal cancer, the anti-vascular endothelial growth factor (VEGF) …
metastases from colorectal cancer, the anti-vascular endothelial growth factor (VEGF) …
[PDF][PDF] Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab
During the last 5 years, numerous publications have demonstrated the potential value of
chemotherapy in downstaging patients with hepatic metastasis from colorectal cancer …
chemotherapy in downstaging patients with hepatic metastasis from colorectal cancer …
[HTML][HTML] Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases
Background Little is known about the safety of the anti-VEGF antibody bevacizumab in
patients undergoing resection for colorectal liver metastases (CLM). This meta-analysis …
patients undergoing resection for colorectal liver metastases (CLM). This meta-analysis …
Bevacizumab allows preservation of liver function and its regenerative capacity after major hepatectomy
A Valverde, R Ciria… - Anti-Cancer Agents …, 2019 - ingentaconnect.com
Background: Parallel to the safety of liver resections, new chemotherapy drugs have
emerged for the control of liver metastases. However, there is unclear evidence about the …
emerged for the control of liver metastases. However, there is unclear evidence about the …
Postoperative liver function recovery after hepatic resection for colorectal metastases previously treated with bevacizumab
R Adam, DA Wicherts, RJ de Haas, F Lévi… - Journal of Clinical …, 2009 - ascopubs.org
4093 Background: The influence of bevacizumab on postoperative morbidity in patients with
colorectal liver metastases (CLM) submitted to hepatectomy has been evaluated. However …
colorectal liver metastases (CLM) submitted to hepatectomy has been evaluated. However …
[HTML][HTML] Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation
P Starlinger, L Alidzanovic, D Schauer, T Maier… - British journal of …, 2012 - nature.com
Background: When anti-VEGF (vascular endothelial growth factor) antibody bevacizumab is
applied in neoadjuvant treatment of colorectal cancer patients with liver metastasis, 5–6 …
applied in neoadjuvant treatment of colorectal cancer patients with liver metastasis, 5–6 …
Related searches
- major hepatectomy liver regeneration
- growth factor liver regeneration
- impact of bevacizumab liver regeneration
- preoperative bevacizumab liver metastases
- impact of bevacizumab hepatectomy in rats
- major hepatectomy liver vessels
- major hepatectomy liver function
- hepatectomy in rats liver regeneration
- impact of bevacizumab liver in patients
- impact of bevacizumab liver metastases
- era of bevacizumab liver metastasis